Mariano R. Gabri

B C1425FQB, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

N-Glycosylation as a Key Requirement for the Positive Interaction of Integrin and uPAR in Glioblastoma.

N-Glycosylation as a Key Requirement for the Positive Interaction of Integrin and uPAR in Glioblastoma.

Journal: International journal of molecular sciences

Published: April 21, 2025

Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.

Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer.

Journal: Translational lung cancer research

Published: March 01, 2025

Terminally sialylated and fucosylated complex N-glycans are involved in the malignant behavior of high-grade glioma.

Terminally sialylated and fucosylated complex N-glycans are involved in the malignant behavior of high-grade glioma.

Journal: Oncotarget

Published: August 29, 2020

A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development.

A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development.

Journal: JMIR public health and surveillance

Published: April 01, 2020

Expression of bladder cancer-associated glycans in murine tumor cell lines.

Expression of bladder cancer-associated glycans in murine tumor cell lines.

Journal: Oncology letters

Published: July 16, 2018

Aberrant O-glycosylation modulates aggressiveness in neuroblastoma.

Aberrant O-glycosylation modulates aggressiveness in neuroblastoma.

Journal: Oncotarget

Published: January 26, 2018

Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.

Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: September 22, 2017

Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.

Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.

Journal: Oncotarget

Published: April 18, 2017

Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival.

Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival.

Journal: JAMA ophthalmology

Published: October 28, 2016

Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.

Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: April 08, 2016

Racotumomab for treating lung cancer and pediatric refractory malignancies.

Racotumomab for treating lung cancer and pediatric refractory malignancies.

Journal: Expert opinion on biological therapy

Published: February 24, 2016

Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.

Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.

Journal: Clinical & experimental metastasis

Published: September 22, 2015

Showing 1-12 of 22

Last Updated: 09/26/2026